May 20, 2020

Gartner: Four ways to address IoT device attack

Gartner Symposium/ITxpo in Cape Town
Internet of Things (IoT) devices Asia
Infrastructure and operations (I&O) leaders
Tim Zimmermann
3 min
Gartner: Four ways to address IoT device attack

By 2020, 21 billion of Internet of Things (IoT) devices will be in use worldwide. Of these, close to 6 percent will be in use for industrial IoT applications. However, IT organisations have issues identifying these devices and characterising them as part of current network access policy.
 

Gartner has recently stated that infrastructure and operations (I&O) leaders must therefore update their network access policy to seamlessly address the onslaught of IoT devices. Business Review Asia takes a look.

1. Know the scale
 

"Having embraced a bring-your-own-device strategy, organisations must now get employee devices on the enterprise network and start addressing the 21 billion IoT devices that we project will want access to the enterprise network," said Tim Zimmermann, research vice president at Gartner ahead of the IoT security track at the Gartner Symposium/ITxpo in Cape Town later this month.

As the business world becomes more connected – and, perhaps, more dependent – on the use of IoT, the potential for an attacker to slip through the ever expanding net could potentially increase.

 2. Maintain control
 

Zimmermann said: "Whether a video surveillance camera for a parking lot, a motion detector in a conference room or the HVAC for the entire building, the ability to identify, secure and isolate all IoT devices — and in particular "headless" devices — is more difficult to manage and secure.

He also explained that it is important that the IT organisation works directly with facilities management and other business units to identify all devices and projects connected to the enterprise infrastructure and attaching to the network.

3. Have robust access policy
 

Once all of the devices attached to the network are identified, the IT organisation must create or modify the network access policy as part of an enterprise policy enforcement strategy. This should determine if and how these devices will be connected, as well as what role they will be assigned that will govern their access.

In order to monitor access and priority of IoT devices, I&O leaders need to consider additional enterprise network best practices. These can be defining a connectivity policy, as many IoT devices will be connected via Wi-Fi; performing spectrum planning — many IoT devices may be using 2.4GHz, but may not be using 802.11 protocols such as Bluetooth, ZigBee or Z-Wave, which may create interference; or considering packet sniffers to identify devices that may do something undesirable on the network.

4. Consider virtual segments
 

While more IoT devices are added to the enterprise network, I&O leaders will need to create virtual segments. These will allow network architects to separate all IoT assets (such as LED lights or a video camera) from other network traffic, supporting each FM application or BU process from other enterprise applications and users.

As the concept of virtual segments continues to mature, the capabilities will allow network architects to prioritise the traffic of differing virtual segments as compared with the rest of the traffic on the network. For example, security video traffic and normal enterprise application traffic may have a higher priority than LED lighting.

Analysts will further discuss how organisations need to plan for the digital future during Gartner Symposium/ITxpo 2016 Follow news and updates on Twitter using#GartnerSYM.
 

The September issue of Business Review Australia & Asia is now live..

Follow @BizRevAsia and @MrNLon on Twitter.

Business Review Asia is also on Facebook. 

Share article

Jun 13, 2021

Seo JungJin: Who is EY’s World Entrepreneur of 2021?

EY
entrepreneurs
Leadership
celltrion
Kate Birch
3 min
From just US$45,000 capital in 2003 to a world-leading biopharma giant with revenues of US$1.69bn today, Seo JungJin is crowned EY World Entrepreneur 2021

Seo JungJin, founder of biopharma firm Celltrion, which most recently developed an antibody treatment for COVID-19, has been named the EY World Entrepreneur of the Year 2021, becoming the first South Korean in the award’s 21-year history.

Regarded as one of the world’s most prestigious business awards program for entrepreneurs, the EY Entrepreneur of the Year celebrates visionary and innovative leaders from across 60 countries who are transforming the world and fostering growth.

JungJin, who is now honoroary chairman of Celltrion Group, was up against a worthy cast of entrepreneurial competitors, taking the crown from among 45 award winners across 38 countries and territories.

Speaking during the virtual event, JungJin described his own interpretation of entrepreneurship as something that brings together “a group of people toward a common vision, embracing challenges as opportunities and committing oneself to contribute to the greater good”.

Why was JungJin crowned King Entrepreneur?

A South Korean native and now 63 years of age, JungJin founded biopharmaceutical firm Celltrion in 2003. In the nearly two decades since its founding, Celltrion has lived up to its goal of advancing health and welfare for all by developing ground-breaking drugs to treat autoimmune disease, various forms of cancer and, most recently, COVID-19.

The company, which JungJin started with just US$45,000 and five of his colleagues, has since growth to more than 2,1000 employees with sales permits in more than 90 countries and revenues exceeding US$1.69bn.

According to the panel, JungJin’s story is a shining example of the power of an unstoppable entrepreneur to change the world with the pandel moved by both his incredible story and his purpose-driven leadership, innovative mindset and entrepreneurial spirit.

Described by the chair of the EY judging panel Rosaleen Blair as “representing everything an unstoppable should be” from taking on the world’s biggest health care challenges to consistently creating long-term value for his company, JungJin’s story is one of incredible tenacity and perseverance that the judging panel felt most represented the entrepreneurial spirit.

“He’s taken breathtaking risks, both personal and professional, to found Celltrion and grow it into one of the world’s leading biopharmaceutical companies,” says Stasia Mitchell, EY Global Entrepreneurship Leader. “His passion for creating affordable, life-saving health care and flair for tackling global problems has led to many treatments that have helped millions of people worldwide and was especially evident this past year through the creation of a COVID-19 antibody treatment.”

How did JungJin get there?

JungJin's entrepreneurial journey started at an early age when he worked as a taxi driver to get himself through Konkuk University in Seoul, South Korea. After studying industrial engineering, he rose through the ranks of Daewoo Motor Co. before losing his job amid the carmaker’s financial troubles following the 1997 Asian economic crisis.

Following this, JungJin started collaborating with colleagues to explore business opportunities in different industries, though none delivered lasting success. The turning point came after he attended a talk hosted by renowned scholars, which inspired him to focus on the biopharmaceutical sector.

And so he founded Celltrion with just US$45,000 of his savings. The launch of Remsima, credited with being the world's first antibody biosimilar, quickly moved Celltrion up the ranks of the country's fairly underdeveloped pharmaceutical sector. Celltrion followed this success with the launch of drugs for breast cancer and lymphoma that today are being used worldwide.

With ambitions to be the world’s first in different areas, Celltrion has pioneered numerous uncharted areas to great success over the past two decades, most recently responding to the global pandemic by successfully developing an antibody treatment for COVID-19 and working to ensure a timely supply of the safe and effective treatment.

“When I first started, my vision was to help patients gain access to safe, effective and affordable medicines and thereby enhance the quality of people’s lives,” explains JungJin. “The success of Celltrion has enabled me to expand on this while finding new ways to fuel my entrepreneurial drive.”

 

Share article